Islet Cell Associated Autoantibodies and C-Peptide Levels in Patients with
Diabetes and Symptoms of Gastroparesis.
Authors Siraj ES, Homko C, Wilson LA, May P, Rao AD, Calles J, Farrugia G, Hasler WL,
Koch KL, Nguyen L, Snape WJ, Abell TL, Sarosiek I, McCallum RW, Pasricha PJ,
Clarke J, Tonascia J, Hamilton F, Parkman HP
Submitted By Thomas Abell on 3/27/2018
Status Published
Journal Frontiers in endocrinology
Year 2018
Date Published
Volume : Pages 9 : 32
PubMed Reference 29487566
Abstract Individuals with diabetes are at increased risk for complications, including
gastroparesis. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder
resulting in decreased beta-cell function. Glutamic acid decarboxylase-65
antibody (GADA) is the most commonly used test to assess autoimmunity while
C-peptide level is used to assess beta-cell function. Patients with type 2
diabetes mellitus (T2DM), who are GADA positive, are labeled latent autoimmune
diabetes in adults (LADA)., To characterize patients with T1 and T2DM who have
symptoms of gastroparesis using GADA and C-peptide levels and to look for
association with the presence of gastroparesis and its symptom severity., 113
T1DM and 90 T2DM patients with symptoms suggestive of gastroparesis were
studied. Symptom severity was assessed using Gastroparesis Cardinal Symptom
Index (GCSI). Serum samples were analyzed for GADA and C-peptide., Delayed
gastric emptying was present in 91 (81%) of T1DM and 60 (67%) of T2DM patients
(p?=?0.04). GADA was present in 13% of T2DM subjects [10% in delayed gastric
emptying and 20% in normal gastric emptying (p?=?0.2)]. Gastric retention and
GCSI scores were mostly similar in GADA positive and negative T2DM patients.
GADA was present in 45% of T1DM subjects [46% in delayed gastric emptying and
41% in normal gastric emptying (p?=?0.81)]. Low C-peptide levels were seen in
79% T1DM patients and 8% T2DM. All seven T2DM patients with low C-peptide were
taking insulin compared to 52% of T2DM with normal C-peptide., GADA was present
in 13% while low C-peptide was seen in 8% of our T2DM patients with symptoms of
gastroparesis. Neither did correlate with degree of delayed gastric emptying or
symptom severity., NCT01696747.

Complications